EXPAND THE COMPACK

(Complete Treatment Pack)

A FILIPINO SHOULD DIE ONLY WHEN THERE IS NOTHING ELSE WE CAN DO, NOT WHEN THERE
IS JUST NOTHING HE CAN DO

INTRODUCTION
Poverty incidence statistics
31m poor in the Philippines
40 percent of the population
to establish and implement generic medicine policies not
just as a program but a law mandated to assure a
continuous accessibility and availability of free medicine
for poorest segment of the population who arent able to
sustain, and not even avail an out-of-pocket treatment
regimen.

Transition in Causes of Death:

More people have been dying of lifestylerelated diseases.
Communicable Diseases
Cancer
Diseases of the Heart

Source: Philippine Health Statistics, 1959-2009

Living longer and older

Getting sick and dying of NCDs

How disease factors affect

Health financing

NONCOMMUNICABLE DISEASES comprise

61% of total deaths in 2010.

Other NCDs; 13
Diabetes; 4

Communicable, maternal, perinatal, and nutritional conditions; 30

Respiratory diseases; 5
Cancers; 10
Injuries; 8
Cardiovascular diseases; 30
Source: WHO, 2010
4
Living longer and older

Getting sick and dying of NCDs

How disease factors affect

Health financing

Paying for Health Care in the

Philippines
Filipinos still
pay mostly from
out of their
pockets for
health care,
which
oftentimes
leads to
impoverishment
.

Health care
costs remain
high, with the
bulk being
spent to cover
for medicines
and drugs..

Medicines in the
Philippines have
been found to
be 5 to 30
times more
expensive.

5
Living longer and older

Getting sick and dying of NCDs

How disease factors affect

Health financing

Filipino households spend 68% of its

out-of-pocket payments for health care
just for DRUGS AND MEDICINES alone.

16%
4%
8%
4%
68%

Drugs and
Medicine
Hospital Charges
Professional fees
Contraceptives
Others

Households' out-of-pocket payments, by expenditure item, 2006

Source: Family Income and Expenditure Survey, 2006
Living longer and older

Getting sick and dying of NCDs

How disease factors affect

Health financing

DOH, 2009
Drugs

Selling Price of
Common Brand Php
(A)

P100 Selling Price Php (B)

DOH Php Savings (A-B)

Allopurinol 100 mg tab

204.90

50.00

154.90

Amlodipine 10 mg tab

448.50

100.00

348.50

Amlodopine 5 mg tab

507.00

100.00

407.00

Amoxicillin 500 mg cap

214.20

70.00

144.20

Ascorbic Acid 500 mg tab

169.50

50.00

119.50

Atenolol 50 mg tab

403.90

70.00

333.90

Cefalexin 500 mg cap

561.75

100.00

461.75

Ciproflaxacin 500 mg tab

Clindamycin 150 mg cap

1,120.00

100.00

1,020.00

Cotrimoxazole 160 mg tab

382.20

25.00

357.20

Felodopine ER 10 mg tab

196.11

100.00

96.11

Felodipine ER 2.5 mg tab

198.80

100.00

98.80

Felodipine ER 5 mg tab

201.85

100.00

101.85

Glibenclamide 5 mg tab

306.00

25.00

281.00

Melformin 500 mg tab

733.50

100.00

633.50

Metropolol 100 mg

786.00

100.00

686.00

RELEVANT POLICIES
R.A 6675- Generics Act of 1988
The Act aims to promote, require and
ensure the production supply,
distribution, use and acceptance of
drugs and medicines using their
generic names.

RELEVANT POLICIES
Administrative Order No. 62 series of
1989, Rules and Regulations to
implement prescribing Requirements
under the Generics Act of 1988.
The generic name of the drug must be
clearly written on the prescription
immediately after the Rx symbol.

RELEVANT POLICIES
R.A 9502- Universally Accessible Cheaper
and Quality Medicines Act of 2008
To ensure the availability of affordable
medicines and to reduce the cost of
medicines especially those that are
commonly bought by the poor that includes
medicines for chronic illnesses, for prevention
of diseases, and those found in the Philippine
National Drug Formulary Essential Drug List.

CONCEPTUAL FRAMEWORK

Income

Family support

Information
sources

Chronically
ill patient

Patient
expectations/
beliefs
Social
approval
Drug
affordability

Program
promotion
Drug
promotion
Availability of
treatment
guidelines

Medication
adherence

RECOMMENDATION
Guaranteed access to free basic and
maintenance medicine.
Dissemination of health information and
education focusing on adherence and
compliance to treatment regimen.
Availability of budget will also determine
whether the policy can expand to
include other chronic diseases
Additional essential medicine

RECOMMENDATION
Allocation process should be flexible
Allocation decision should focus on
areas with highest prevalence of the
poorest of the poor without favoritism.
Periodic assessment and evaluation of
the effectiveness and efficiency of the
proposed policy.
Awareness to patients about Complete
Treatment Pack

THANK YOU